Home›Suvorexant

Suvorexant

Also known as: Belsomra

Orexin Receptor AntagonistOrexin Receptor AntagonistsP-Glycoprotein Inhibitors

Route: Oral

Check Suvorexant Interactions →

29 interactions on record

Suvorexant has 29 known drug interactions based on U.S. FDA drug labeling data. Of these, 13 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Boceprevir, Clarithromycin, Conivaptan. Patients taking Suvorexant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 29
Contraindicated: 13
Major: 3
Moderate: 13

Contraindicated (13)

Suvorexant + Boceprevir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Clarithromycin— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Conivaptan— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Indinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Itraconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Ketoconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Nefazodone— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Nelfinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Posaconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Ritonavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Saquinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Telaprevir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Telithromycin— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Major (3)

Suvorexant + Carbamazepine— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.
Suvorexant + Phenytoin— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.
Suvorexant + Rifampin— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Moderate (13)

Suvorexant + Alcohol— Additive psychomotor impairment demonstrated when co-administered with suvorexant.
Suvorexant + Amprenavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Aprepitant— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Atazanavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Ciprofloxacin— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Digoxin— Suvorexant slightly increases digoxin levels by inhibiting intestinal P-gp; monitor digoxin concentrations.
Suvorexant + Diltiazem— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Erythromycin— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Fluconazole— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Fosamprenavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Grapefruit Juice— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Imatinib— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Verapamil— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Boceprevir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Clarithromycin⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Conivaptan⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Indinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Itraconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Ketoconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Nefazodone⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Nelfinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Posaconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Ritonavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Saquinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Telaprevir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Telithromycin⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Carbamazepine⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Phenytoin⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Rifampin⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Alcohol🟡Moderate

Additive psychomotor impairment demonstrated when co-administered with suvorexant.

Suvorexant + Amprenavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Aprepitant🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Atazanavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Ciprofloxacin🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Digoxin🟡Moderate

Suvorexant slightly increases digoxin levels by inhibiting intestinal P-gp; monitor digoxin concentrations.

Suvorexant + Diltiazem🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Erythromycin🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Fluconazole🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Fosamprenavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Grapefruit Juice🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Imatinib🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Verapamil🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.